(BN) Danone - Ratings and Ratios
Dairy, Plant-Based, Specialized Nutrition, Waters
BN EPS (Earnings per Share)
BN Revenue
Description: BN Danone
Danone SA is a multinational food and beverage company operating in various regions worldwide, including Europe, North America, and Asia. The company is organized into three main business segments: Essential Dairy & Plant-Based, Specialized Nutrition, and Waters. Its diverse product portfolio includes yogurts, dairy products, plant-based products, ice creams, frozen desserts, cheese products, and mineral waters, among others.
The companys brands, such as Actimel, Activia, Alpro, and evian, are well-established in the market, and its products are distributed through various channels, including retail chains, convenience stores, hotels, restaurants, and e-commerce platforms. Danones focus on healthy and sustainable food options positions it well in the growing market for nutritious and environmentally friendly products.
From a financial perspective, Danones market capitalization stands at approximately €44.4 billion, with a price-to-earnings ratio of 22.07 and a forward P/E of 19.05. The companys return on equity (RoE) is 17.21%, indicating a relatively strong profitability. To further evaluate Danones performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating margin can be examined. For instance, Danones revenue growth has been driven by its focus on healthy and sustainable products, with a reported CAGR of 4-5% in recent years. Additionally, the companys gross margin has remained stable at around 40-45%, indicating a relatively efficient cost structure.
To assess Danones competitive position and potential for future growth, it is essential to analyze its market share, brand recognition, and product innovation capabilities. Danones strong brand portfolio and diversified product offerings enable it to compete effectively in the packaged foods and beverages market. Furthermore, the companys commitment to sustainability and healthy eating aligns with the growing consumer demand for environmentally friendly and nutritious products.
BN Stock Overview
| Market Cap in USD | 54,395m |
| Sector | Consumer Defensive |
| Industry | Packaged Foods |
| GiC Sub-Industry | Packaged Foods & Meats |
| IPO / Inception |
BN Stock Ratings
| Growth Rating | 61.5 |
| Fundamental | 73.2% |
| Dividend Rating | 55.7 |
| Rel. Strength | 0.58 |
| Analysts | - |
| Fair Price Momentum | 72.62 EUR |
| Fair Price DCF | 95.44 EUR |
BN Dividends
| Dividend Yield 12m | 3.13% |
| Yield on Cost 5y | 4.63% |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 99.2% |
| Payout Ratio | 75.4% |
BN Growth Ratios
| Growth Correlation 3m | -73.5% |
| Growth Correlation 12m | 82.6% |
| Growth Correlation 5y | 78% |
| CAGR 5y | 8.95% |
| CAGR/Max DD 5y | 0.33 |
| Sharpe Ratio 12m | 0.17 |
| Alpha | 21.88 |
| Beta | -0.208 |
| Volatility | 22.52% |
| Current Volume | 895.7k |
| Average Volume 20d | 1067.8k |
| Stop Loss | 69.7 (-3.1%) |
As of August 10, 2025, the stock is trading at EUR 71.90 with a total of 895,671 shares traded.
Over the past week, the price has changed by -0.83%, over one month by +6.39%, over three months by -3.10% and over the past year by +22.22%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, Danone (PA:BN) is currently (August 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 73.15 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BN is around 72.62 EUR . This means that BN is currently overvalued and has a potential downside of 1%.
Danone has no consensus analysts rating.
According to our own proprietary Forecast Model, BN Danone will be worth about 78.4 in August 2026. The stock is currently trading at 71.90. This means that the stock has a potential upside of +9.08%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 74.5 | 3.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 78.4 | 9.1% |
Piotroski VR‑10 (Strict) 5.5
| Net Income (2.85b TTM) > 0 and > 6% of Revenue (6% = 3.27b TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 3.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -1.32% (prev -3.67%; Δ 2.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 7.37b > Net Income 2.85b (YES >=105%, WARN >=100%) |
| Net Debt (13.33b) to EBITDA (6.65b) ratio: 2.00 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.95 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (643.3m) change vs 12m ago 0.27% (target <= -2.0% for YES) |
| Gross Margin 49.46% (prev 46.67%; Δ 2.79pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 122.3% (prev 76.08%; Δ 46.26pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.65 (EBITDA TTM 6.65b / Interest Expense TTM 947.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.44
| (A) -0.02 = (Total Current Assets 12.90b - Total Current Liabilities 13.62b) / Total Assets 43.76b |
| (B) 0.38 = Retained Earnings (Balance) 16.73b / Total Assets 43.76b |
| (C) 0.10 = EBIT TTM 4.41b / Avg Total Assets 44.60b |
| (D) 0.61 = Book Value of Equity 16.90b / Total Liabilities 27.89b |
| Total Rating: 2.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay Score 73.15
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 8.26% = 4.13 |
| 3. FCF Margin 8.04% = 1.34 |
| 4. Debt/Equity 0.79 = 2.20 |
| 5. Debt/Ebitda 1.88 = 0.24 |
| 6. ROIC - WACC 6.73% = 6.73 |
| 7. RoE 17.09% = 2.85 |
| 8. Rev. Trend 43.96% = 5.0 |
| 9. Rev. CAGR 6.12% = 0.77 |
| 11. EPS CAGR -4.86% = -0.61 |
BN Fundamental Data Overview
Market Cap EUR = 46.64b (46.64b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 6.01b EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 25.4386
P/E Forward = 20.0
P/S = 1.7049
P/B = 2.9403
P/EG = 2.8986
Beta = 0.389
Revenue TTM = 54.56b EUR
EBIT TTM = 4.41b EUR
EBITDA TTM = 6.65b EUR
Long Term Debt = 9.88b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.63b EUR (from shortTermDebt, last quarter)
Debt = 12.51b EUR (Calculated: Short Term 2.63b + Long Term 9.88b)
Net Debt = 13.33b EUR (from netDebt column, last fiscal year)
Enterprise Value = 53.13b EUR (46.64b + Debt 12.51b - CCE 6.01b)
Interest Coverage Ratio = 4.65 (Ebit TTM 4.41b / Interest Expense TTM 947.0m)
FCF Yield = 8.26% (FCF TTM 4.39b / Enterprise Value 53.13b)
FCF Margin = 8.04% (FCF TTM 4.39b / Revenue TTM 54.56b)
Net Margin = 5.21% (Net Income TTM 2.85b / Revenue TTM 54.56b)
Gross Margin = 49.46% ((Revenue TTM 54.56b - Cost of Revenue TTM 27.58b) / Revenue TTM)
Tobins Q-Ratio = 3.14 (Enterprise Value 53.13b / Book Value Of Equity 16.90b)
Interest Expense / Debt = 3.43% (Interest Expense 429.0m / Debt 12.51b)
Taxrate = 30.98% (from yearly Income Tax Expense: 929.0m / 3.00b)
NOPAT = 3.04b (EBIT 4.41b * (1 - 30.98%))
Current Ratio = 0.95 (Total Current Assets 12.90b / Total Current Liabilities 13.62b)
Debt / Equity = 0.79 (Debt 12.51b / last Quarter total Stockholder Equity 15.86b)
Debt / EBITDA = 1.88 (Net Debt 13.33b / EBITDA 6.65b)
Debt / FCF = 2.85 (Debt 12.51b / FCF TTM 4.39b)
Total Stockholder Equity = 16.64b (last 4 quarters mean)
RoA = 6.50% (Net Income 2.85b, Total Assets 43.76b )
RoE = 17.09% (Net Income TTM 2.85b / Total Stockholder Equity 16.64b)
RoCE = 16.62% (Ebit 4.41b / (Equity 16.64b + L.T.Debt 9.88b))
RoIC = 11.37% (NOPAT 3.04b / Invested Capital 26.76b)
WACC = 4.64% (E(46.64b)/V(59.15b) * Re(5.25%)) + (D(12.51b)/V(59.15b) * Rd(3.43%) * (1-Tc(0.31)))
Shares Correlation 5-Years: -10.0 | Cagr: -0.13%
Discount Rate = 5.25% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 77.05% ; FCFE base≈3.90b ; Y1≈3.68b ; Y5≈3.49b
Fair Price DCF = 95.44 (DCF Value 61.39b / Shares Outstanding 643.3m; 5y FCF grow -7.05% → 2.90% )
Revenue Correlation: 43.96 | Revenue CAGR: 6.12%
Revenue Growth Correlation: 7.65%
EPS Correlation: N/A | EPS CAGR: -4.86%
EPS Growth Correlation: 40.02%